Technical Analysis for NTLA - Intellia Therapeutics, Inc.

Grade Last Price % Change Price Change
B 74.6 7.14% 4.97
NTLA closed up 7.14 percent on Thursday, April 22, 2021, on 70 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical NTLA trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Multiple of Ten Bullish Other 0.00%
Up 3 Days in a Row Strength 0.00%
20 DMA Resistance Bearish 7.14%
50 DMA Support Bullish 7.14%
Expansion Pivot Buy Setup Bullish Swing Setup 7.14%
Pocket Pivot Bullish Swing Setup 7.14%
Multiple of Ten Bearish Other 7.14%
Wide Bands Range Expansion 7.14%
50 DMA Support Bullish 10.67%
Older End-of-Day Signals for NTLA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 10% about 20 hours ago
Up 1 ATR about 21 hours ago
Expansion Pivot Entry about 22 hours ago
Rose Above Previous Day's High about 22 hours ago
Up 5% about 22 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Intellia Therapeutics, Inc. Description

Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. It has a strategic collaboration and license agreement with Novartis focused on the development of new ex vivo CRISPR/Cas9-based therapies. Intellia Therapeutics Inc. was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics Inc. in July 2014. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biology Immune System Emerging Technologies Genetics Molecular Biology Hepatitis B Metabolism Precision Medicine Liver Disease Amyloid Hematopoietic Stem Cell Hepatitis B Virus Chimeric Antigen Receptor Liver Diseases Amyloidosis Antitrypsin Deficiency Cell Product Chimeric Antigen Receptor T Cell CRISPR Genome Editing Inborn Errors Of Metabolism Transthyretin Cas9 Transthyretin Amyloidosis

Is NTLA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 91.9999
52 Week Low 12.32
Average Volume 1,375,068
200-Day Moving Average 43.78
50-Day Moving Average 66.86
20-Day Moving Average 72.02
10-Day Moving Average 71.04
Average True Range 6.50
ADX 10.47
+DI 26.47
-DI 24.16
Chandelier Exit (Long, 3 ATRs ) 66.39
Chandelier Exit (Short, 3 ATRs ) 73.60
Upper Bollinger Band 82.34
Lower Bollinger Band 61.71
Percent B (%b) 0.62
BandWidth 28.64
MACD Line 1.17
MACD Signal Line 1.66
MACD Histogram -0.4929
Fundamentals Value
Market Cap 4.41 Billion
Num Shares 59.1 Million
EPS -2.00
Price-to-Earnings (P/E) Ratio -37.23
Price-to-Sales 36.49
Price-to-Book 7.69
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 86.74
Resistance 3 (R3) 86.06 81.33 84.71
Resistance 2 (R2) 81.33 78.24 81.67 84.04
Resistance 1 (R1) 77.97 76.33 79.65 78.65 83.36
Pivot Point 73.24 73.24 74.09 73.58 73.24
Support 1 (S1) 69.88 70.15 71.56 70.56 65.84
Support 2 (S2) 65.15 68.24 65.49 65.16
Support 3 (S3) 61.79 65.15 64.49
Support 4 (S4) 62.47